Cell‐Free DNA Screening After Euploid Embryo Transfer: Concordance With Amniocentesis and Residual Aneuploidy Risk
Prenatal Diagnosis · 2026
DOI: 10.1002/pd.70249 ↗At a glance
Journal article in Prenatal Diagnosis, 2026. Written by Yao Lu and 7 co-authors. Institution: Department of Reproductive Medicine, Shanghai Key Laboratory for Assisted Reproduction and Reproductive Genetics, Ren Ji Hospital, Shanghai Jiao Tong…. Major MEDLINE topics: Aneuploidy, Cell-Free Nucleic Acids, Amniocentesis, Embryo Transfer. 26 references. Funded by: National Key Research and Development Program of China, National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality.
Abstract (original language)
Objective
To assess concordance between cell‐free DNA screening and invasive prenatal diagnosis after single euploid embryo transfer following pre‐implantation genetic testing for aneuploidy (PGT‐A), and estimate residual chromosomal risk.
Method
This retrospective cohort included 1079 singleton ongoing pregnancies after PGT‐A between August 2019 and March 2024. Prenatal testing comprised cell‐free DNA screening alone ( n = 317), amniocentesis alone ( n = 500), or both tests ( n = 262). Chromosomal microarray analysis of amniocytes was the reference standard.
Results
In the dual‐testing cohort, eight pregnancies had high‐risk cell‐free DNA results, of which one was confirmed as 47, XXX. One low‐risk result was subsequently diagnosed as sex chromosome mosaicism. Sensitivity, specificity, positive predictive value and negative predictive value were 50.0% (95% CI, 2.7–97.3), 97.3% (94.3–98.8), 12.5% (0.6–53.3) and 99.6% (97.5–99.9), respectively. Among 762 pregnancies undergoing amniocentesis, residual confirmed aneuploidy risk after euploid embryo transfer was 0.1% (1/762). The overall yield of clinically relevant CMA findings was 0.5% (4/762), including two pathogenic microdeletions. One pregnancy loss within 7 days after amniocentesis occurred (0.1%).
Conclusion
After PGT‐A, cell‐free DNA screening showed high negative predictive value but limited positive predictive value. These findings support risk‐stratified prenatal testing, while invasive diagnosis remains indicated after high‐risk screening, abnormal ultrasound, or patient preference.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Reproductive Medicine, Shanghai Key Laboratory for Assisted Reproduction and Reproductive Genetics, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Shanghai Immune Therapy Institute, Shanghai Jiao Tong University School of Medicine-Affiliated Renji Hospital, Shanghai, China.
ORCID profiles: Ting Zhang, Yun Sun
Funding
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
- SJTU Kunpeng&Ascend Center of Excellence
- Shanghai's Top Priority Research Center Construction Project
- Clinical Cohort Shanghai
Cite
APA
Lu, Y., He, Y., Huang, Y., Niu, Y., Zhang, S., Zhang, Y., Zhang, T., & Sun, Y. (2026). Cell‐Free DNA Screening After Euploid Embryo Transfer: Concordance With Amniocentesis and Residual Aneuploidy Risk. Prenatal Diagnosis. https://doi.org/10.1002/pd.70249
Vancouver
Lu Y, He Y, Huang Y, Niu Y, Zhang S, Zhang Y, et al. Cell‐Free DNA Screening After Euploid Embryo Transfer: Concordance With Amniocentesis and Residual Aneuploidy Risk. Prenatal Diagnosis. 2026. doi:10.1002/pd.70249
BibTeX
@article{Lu2026,
author = {Lu, Yao and He, Yaqiong and Huang, Yi and Niu, Yichao and Zhang, Shuo and Zhang, Yueping and Zhang, Ting and Sun, Yun},
title = {Cell‐Free DNA Screening After Euploid Embryo Transfer: Concordance With Amniocentesis and Residual Aneuploidy Risk},
journal = {Prenatal Diagnosis},
year = {2026},
doi = {10.1002/pd.70249}
}
EUVIMED